Related Experiment Video

Updated: Aug 17, 2026

A Platform of Anti-biofilm Assays Suited to the Exploration of Natural Compound Libraries
09:39

A Platform of Anti-biofilm Assays Suited to the Exploration of Natural Compound Libraries

Published on: December 27, 2016

Efficacy of imipenem in experimental group B streptococcal bacteremia and meningitis

K S Kim

    Chemotherapy
    |January 1, 1985
    PubMed

    Insights

    Imipenem demonstrated potent bactericidal activity against a type III group B streptococcal strain in vitro. In infant rats, imipenem effectively treated bacteremia and meningitis, reducing mortality and preventing disease development.

    Area of Science:

    • Microbiology
    • Infectious Diseases
    • Pharmacology

    Background:

    • Group B Streptococcus (GBS) is a significant cause of neonatal infections, including bacteremia and meningitis.
    • Effective antimicrobial therapies are crucial for combating GBS infections, particularly in vulnerable infant populations.

    Purpose of the Study:

    • To evaluate the in vitro and in vivo efficacy of imipenem against a specific type III group B streptococcal strain.
    • To assess imipenem's impact on bacterial clearance, sterilization, meningitis prevention, and mortality in an infant rat model.

    Main Methods:

    • In vitro determination of minimal inhibitory and bactericidal concentrations (MICs and MBCs) of imipenem.
    • In vivo studies utilizing an infant rat model of GBS-induced bacteremia and meningitis.
    • Assessment of bacterial load in blood and cerebrospinal fluid (CSF), mortality rates, and development of meningitis.

    Main Results:

    • Imipenem exhibited minimal inhibitory and bactericidal concentrations of 15 mg/l against the GBS strain.
    • In vivo, imipenem led to rapid bacterial clearance and sterilization of blood and CSF.
    • Imipenem significantly reduced mortality and prevented meningitis development in infected infant rats.

    Conclusions:

    • Imipenem displays significant bactericidal activity both in vitro and in vivo against type III group B Streptococcus.
    • Imipenem shows promise as an effective therapeutic agent for experimental GBS bacteremia and meningitis in a neonatal model.

    More Related Videos

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

    Published on: January 2, 2017

    Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

    Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

    Published on: January 22, 2021

    Related Concept Videos

    Bacterial Meningitis I: Introduction01:22

    Bacterial Meningitis I: Introduction

    Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
    Bacterial Meningitis II: Pathophysiology01:26

    Bacterial Meningitis II: Pathophysiology

    Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...